EC Number   |
Inhibitors |
Structure |
|---|
    3.5.1.23 | (1R, 2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-propanediol |
inhibits in vitro |
   |
| 3.5.1.23 | (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-propanediol |
potent inhibitor of acid ceramidase |
|
| 3.5.1.23 | (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-propanediol |
- |
|
| 3.5.1.23 | (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-propanediol |
the efficacy of (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-propanediol in vitro as well as in intact cells can be enhanced by suitable modification of functional groups; the efficacy of the inhibitor in vitro as well as in intact cells can be enhanced by suitable modification of functional groups |
|
| 3.5.1.23 | (1R,2R)-2-N-(tetradecanoylamino)-1-(4'-nitrophenyl)-propyl-1,3-O,O-(N,N-dimethylamino)acetate dihydrochloride |
i.e. LCL521 or Di-DMG-B13, is a lysosomotropic inhibitor of ACDase, inhibition mechanism, overview. Low dose of LCL521 (0.001 mM) effectively inhibits ACDase in cells, but the effects are transient. A higher dose of LCL521 (0.01 mM) causes profound decrease of sphingosine and increase of ceramide, but additionally affects the processing and regeneration of the ACDase protein, with biphasic and reversible effects on the expression of ACDase, which parallels the long term changes of cellular sphingosine and ceramide. Finally, the higher concentrations of LCL521 also inhibit dihydroceramide desaturase (DES-1, EC 1.14.19.17). LCL521 inhibits ACDase specifically among the ceramidases in vitro, which is reinforced by the lysosomal targeting |
|
| 3.5.1.23 | (1R,2R)-2-N-myristoylamino-1-(4-nitrophenyl)-1,3-propandiol |
- |
|
| 3.5.1.23 | (1S, 2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol |
inhibitor of alkaline ceramidase; inhibitor of alkaline ceramidase; inhibitor of neutral ceramidase |
|
| 3.5.1.23 | (1S,2R)-2-N-myristoylamino-1-phenyl-1-propanol |
- |
|
| 3.5.1.23 | (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol |
- |
|
| 3.5.1.23 | (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol |
i.e. D-e-MAPP, an alkaline ceramidase inhibitor, that potently and specifically inhibits ACER1, ACER2, and ACER3 activity |
|
